Katherine Stueland

Chief Executive Officer

Katherine Stueland (Chief Executive Officer) filed 14 Form 4 reports in the trailing twelve months (0 purchases, 14 sales), most often in GeneDx Holdings Corp. (WGS). The largest single filing was $3.0M of WGS (46,933 sh across 5 lots, as filed), executed Mar 26.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 14 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$12.3M

shares × price, as filed

Last traded

Sep 16

Filed Sep 18

Median ADV $82.7M across their filed names

Open performance→

Volume by month

Buys $0 Sells $37.1M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 14 filings

Sector per market data · by filing · past 12 months

Most traded names

WGS

GeneDx Holdings Corp. WGS · 0 buys · 33 sells 33 filings

Recent filings

WGSSALE GeneDx Holdings Corp. View filing → $1.0M
10,559 sh × $96.71
Exec Mar 17 2025
Filed Mar 17 2025 · 5:30 PM ET WGSSALE GeneDx Holdings Corp. View filing → $259K
2,731 sh × $94.73
Exec Mar 10 2025
Filed Mar 11 2025 · 5:30 PM ET WGSSALE GeneDx Holdings Corp. View filing → $130K
1,657 sh × $78.48
Exec Jan 29 2025
Filed Jan 31 2025 · 5:30 PM ET WGSSALE GeneDx Holdings Corp. View filing → $4.9M
51,420 sh across 4 lots
Exec Jan 7 2025
Filed Jan 10 2025 · 5:30 PM ET †